# NKT Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nkt-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.nktrx.com
- Total disclosed funding: $8M
- Latest round: Series A (Mar 30, 2009)
- Investors on record: 2

## About

NKT Therapeutics, Inc is a biotechnology company focused on developing innovative therapies that harness the power of natural killer T cells for the treatment of various cancers and autoimmune diseases.Founded in 2008 and headquartered in Waltham, Massachusetts, NKT Therapeutics, Inc specializes in immunotherapy solutions targeting natural killer T cells. In February 2013, the company raised USD 2 million in Series A funding from unspecified investors, marking its initial significant financing event. The company has completed a total of 4 deals since its inception, with the most recent deal occurring on February 13, 2013. The current company valuation stands at USD 25.39 mn.NKT Therapeutics, Inc focuses on developing immunotherapies that leverage natural killer T cells to provide effective treatment options for cancers and autoimmune diseases. Their research aims to create innovative therapeutic candidates that can significantly improve patient outcomes in these challenging medical areas.The company generates revenue primarily through partnerships and collaborations in the biotechnology sector. Their innovative approach to immunotherapy attracts interest from pharmaceutical companies looking to enhance their treatment portfolios, contributing to their overall revenue structure.NKT Therapeutics plans to utilize the recent USD 2 million funding from February 2013 to advance its research and development efforts for new immunotherapy products. The company is actively designing and preparing to launch additional therapies aimed at expanding its treatment options by 2024. Additionally, NKT Therapeutics is looking to penetrate new markets, particularly in Europe and Asia, to broaden the accessibility of its innovative therapies.

## Funding rounds

- Series A, Mar 30, 2009, $8M — SV Health Investors, MedImmune Ventures

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series A